All In Biotech

Drug Trial Radar · NCT05501860

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Evaluation of the Ocular Safety of Articaine Sterile Topical Ophthalmic Solution

Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 249 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

249

Actual

Start

Jul 30, 2022

Primary completion

Dec 7, 2022

Study completion Dec 7, 2022

Sponsor

Lead sponsor
American Genomics, LLCIndustry
Sponsor type
Industry
First posted
Aug 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..

Conditions

  • Anesthesia, Local

Interventions

  • AG-920Drug

    AG-920 Sterile Topical Ophthalmic Solution

  • PlaceboDrug

    Placebo Sterile Topical Ophthalmic Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From Day 1 (treatment day) to 4 days following treatment day; 90 days following treatment for subjects participating in specular microscopy.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • American Genomics Site 1

    Newport Beach, California

  • American Genomics Site 2

    McAllen, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.